Medical devices that look like medicines: safety and regulatory concerns for children in Europe

Abstract

IntroductionMedical devices (MedDevs) and medicines are assessed (and monitored) differently before and after launch. There are products for repeated oral ingestion that are marketed in the European Union as MedDevs.Objectives and methodsTo illustrate the consequences of these differences in assessment, we compared the leaflet information of three MedDevs with the standards for medicines and with published evidence at launch. As examples, gelatin tannate (GT), its combination with tyndalised probiotics (TP) (GTTP) for diarrhoea and a gel containing hyaluronic acid (HA)/chondroitin sulfate (CS)/poloxamer (Pol407) (HACSPol) for gastro-oesophageal reflux disease were examined.ResultsApplying standards for medicines, product composition is insufficiently defined in the MedDev leaflet (eg, plant origin, polymerisation grade, dose and ratio of the relevant constituents). As no age limit is mentioned in the leaflets, all 3 products allow use in children from birth onwards, although published clinical documentation in children was poor (GT) or lacking (GTTP and HACSPol). MedDev leaflets do not mention adverse events (AEs), while literature search suggests safety concerns such as tannic acid (TA) cytotoxicity, potentially more diarrhoea/AEs with TP, use of doses higher than established safe (TA and HA) and lack of chronic toxicity studies for oral Pol407. None refers to interactions with medicines, although some ingredients may affect medicine absorption.ConclusionAlthough these MedDevs require repeated oral intake as do medicines, their assessment and monitoring differ significantly from the standards for medicines. Compared with medicines, MedDevs for repeated oral use are poorly labelled and rely on very limited clinical information at market release.

Does Trypsin Oral Spray (Viruprotect®/ColdZyme®) Protect against COVID-19 and Common Colds or Induce Mutation? Caveats in Medical Device Regulations in the European Union

“…Overall, our evaluation also reflects the current poor quality of the clinical data of MDs, in line with former findings, as well as of the reporting in the public domain, escaping peer review [ 2 , 89 ]. As illustrated in Table 1 and Table 2 , many (pre)clinical study data remained unpublished or were solely and selectively available on the manufacturer’s internet site.…”

“…A scoping internet search by us identified a wealth of promising treatments for the nose and throat against COVID-19, while a number of these sprays are already marketed as medical devices (MDs) in Europe. Such oral or nasal sprays may easily enter the European Economic Area (EEA) as MDs, as MDs are not conditioned the same way as medicines [ 2 , 3 ]. The prerequisites clearly differ from the regulatory requirements needed for registration as a medicine.…”

Pharmacologic treatment of GERD in adolescents: Is esophageal mucosal protection an option?

“…A recent paper from Belgian pediatric gastroenterologists 82 has risen concern about the use of Esoxx and some other GI medical devices in children. Besides regulatory issues, the main criticism was related to the lack of qualitative and quantitative information about its composition (reported in Table 1 ) and the inclusion of poloxamer 407 in the oral formulation, whose special property allows to keep the hyaluronic acid and chondroitin sulfate incorporated in a gel matrix that becomes more viscous at body temperature.…”

Medical Devices Made of Substances: The Need for a Change in Approach in Paediatrics

“…NHPs and MDMS must be subjected to the same ethical scrutiny as traditional medicines. It is fundamental that scientific data is gathered on efficacy and patient safety (Huijghebaert et al, 2020). As with drugs, treatment with any natural product must be individualized and tailored to each patient's circumstances (Huijghebaert et al, 2020).…”

“…It is fundamental that scientific data is gathered on efficacy and patient safety (Huijghebaert et al, 2020). As with drugs, treatment with any natural product must be individualized and tailored to each patient's circumstances (Huijghebaert et al, 2020). It is vital to take into account the stage of the disease, the severity of symptoms, the patient's quality of life and the existence/absence of valid therapeutic alternatives.…”